Illinois Municipal Retirement Fund Sells 20,185 Shares of Boston Scientific Corporation $BSX

Illinois Municipal Retirement Fund reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 11.0% in the third quarter, Holdings Channel reports. The firm owned 163,438 shares of the medical equipment provider’s stock after selling 20,185 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Boston Scientific were worth $15,956,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp grew its position in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the period. Synergy Asset Management LLC boosted its stake in Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC grew its stake in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after acquiring an additional 14,700 shares in the last quarter. Channel Wealth LLC lifted its position in shares of Boston Scientific by 70.8% in the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after buying an additional 11,847 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of Boston Scientific by 106.4% during the 2nd quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock valued at $324,971,000 after acquiring an additional 1,559,605 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BSX shares. JPMorgan Chase & Co. decreased their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Morgan Stanley reduced their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $109.43.

Boston Scientific Stock Up 0.8%

NYSE BSX opened at $74.09 on Friday. The business’s fifty day simple moving average is $91.39 and its 200-day simple moving average is $97.90. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market cap of $109.83 billion, a PE ratio of 38.19, a P/E/G ratio of 1.02 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.